ClinicalTrials.gg
CompletedNCT00793598Updated Aug 16, 2021Results posted

CMX001 in Post-transplant Patients With BK Virus Viruria

A Phase 1/2 interventional study of Placebo and Brincidofovir in Viruria, sponsored by Chimerix. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-16.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.

Read the detailed description

This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus infection.

Subjects received blinded study medication for a total of 5 doses in 1 of the following regimens:

  • 10 mg BCV administered twice weekly (BIW) on Days 0, 3, 7, 10, 14.
  • 20 mg BCV administered once weekly (QW) on Days 0, 7, and 14 and placebo administered on Days 3 or 10.
  • Placebo administered BIW on Days 0, 3, 7, 10 ,14.
  • 40 mg BCV administered QW on Days 0, 7, 14, 21, and 28.
  • Placebo administered QW on Days 0, 7, 14, 21, and 28.
02

Conditions studied

  • Viruria

Keywords

  • CMX001
  • Kidney transplant
  • HSCT transplant
  • BK Virus
  • Post kidney transplant patients with BK virus viruria > 10^4
  • Post HSCT transplant patients with BK virus viruria > 10^4
03

In context

Lead sponsor

Chimerix is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

First submitted before Chimerix became part of Jazz Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion into the trial, subjects were required to fulfill all of the following criteria:

  1. Aged between 18 to 75 years, inclusive. Males must have been able and willing to use adequate methods throughout the study and for 3 months after the final dose. Females must have been , surgically sterile, or willing to use adequate contraception for the duration of the study (screening through the Day 48 visit).
  2. Were renal or hematopoietic stem cell transplant patients who met the following criteria:

    1. Renal transplant patients who:

      • Were at least 28 days post transplant;
      • Were in stable condition with >10 g/100 mL;
      • Had no evidence of graft rejection (i.e., serum creatinine was not increasing [±30%], was not decreasing);
      • Were on a stable regimen for at least 14 days prior to dosing.
      • Had either urine levels of BK virus DNA ≥10\^4 copies/mL without viremia or plasma levels of BK virus DNA \<10\^4 copies/mL (with or without viruria).
    2. Stem cell transplant patients who:

      • Were a minimum of 3 days post documentation of successful engraftment as evidenced by an >500 cells/mm3;
      • Had urine levels of BKV ≥10\^4 copies/mL.
  3. Had >30 mL/min.
  4. Were able to swallow tablets.
  5. Were willing and able to understand and provide written .
  6. Were willing and able to participate in all required study activities for the duration of the study (including ingestion of oral medication).

Exclusion criteria

Exclusion Criteria

Any of the following was regarded as a criterion for exclusion from the trial:

  1. Females who were currently nursing or pregnant.
  2. Were using illicit drugs or abusing alcohol.
  3. Had to cidofovir or brincidofovir.
  4. Had received aminoglycosides (intravenously) or NSAIDS (except as given for cardioprotective treatment) within 7 days prior to enrollment; had received leflunomide, cidofovir, or any other medication for treatment of BK virus infection or disease within 14 days prior to enrollment; had received any drug (including maribavir) within 30 days prior to enrollment.
  5. Were positive (results must have been obtained within 1 year prior to dosing); had active virus (HCV) or virus (HBV) infection as evidenced by plasma levels of HCV RNA or HBV DNA, respectively.
  6. Were renal transplant patients with evidence of proven acute rejection in the 3 weeks prior to enrollment. This exclusion criterion applied only to those patients for whom a biopsy was performed within the 3 weeks prior to enrollment.
  7. Were stem cell transplant patients who:

    1. Had cystitis ≥Grade 3 National Cancer Institute, version 3.0.
    2. Had Grade 3 or 4 (GVHD).
    3. Had untreated or uncontrolled Grade 2 GVHD.
    4. Had received ganciclovir or valganciclovir within 14 days prior to enrollment.
  8. Had mucositis that prevented ingestion of oral medication.
  9. Had hypotony, uveitis, or retinitis or any intraocular pathology that would have predisposed the patient to any one of these conditions.
  10. Had unstable or poorly controlled diabetes, defined as having frequent hypoglycemic and/or hyperglycemic events on a daily basis (brittle diabetes), with fluctuating short acting insulin requirements daily, or requiring unpredictable insulin supplementation to oral hypoglycemic agents on a regular basis.
  11. Had >2.5 x the .
  12. Had cardiovascular disease which, in the opinion of the investigator, would have interfered with the conduct of the study.
  13. Had any of the following diseases: Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid, celiac disease, dermatomyositis, active Goodpasture's syndrome, idiopathic thrombocytopenic purpura, active lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, polymyositis, primary biliary cirrhosis, vasculitis, Wegener's granulomatosis.
  14. Had active (with the exception of basal cell carcinoma or the condition under treatment for hematopoietic stem cell transplant patients).
  15. Had concurrent or ongoing ≥Grade 2 gastrointestinal symptoms including nausea, vomiting, diarrhea, constipation, or gastroenteritis. Patients with active gastrointestinal disease including inflammatory bowel disease, irritable bowel syndrome, or celiac sprue.
  16. Had any other condition including abnormal laboratory values that would have, in the judgement of the investigator, put the subject at increased risk for participating in the trial, or interfered with the conduct of the trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Brincidofovir

    Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows: * 20 mg BCV once weekly (QW) on Days 0, 7, and 14; or * 10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14. Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28.

    Drug: Brincidofovir

  • Placebo comparator
    Placebo

    Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14. Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria

    The primary objective of this study was to determine the safety and tolerability of brincidofovir (BCV) in post-transplant patients with BK virus viruria. Safety measures included adverse events, clinical laboratory values, vital signs, and renal and gastrointestinal function.

    Time frame: 35 days (Day 0 to Day 35)

Secondary outcomes

  1. Percentage of Patients Who Achieved BK Viruria Resolution

    The percentage of subjects who cleared the virus was calculated. Concentrations below the lower limit of quantification were indicated as below the limit of quantitation and were considered "cleared".

    Time frame: 28 days

  2. Number of Patients Who Achieved a Clinically Significant Decrease in BK Viruria

    A 2-log drop in viruria or viremia or clearance of virus was considered significant. Percentages of subjects with a 2-log drop in viral load were calculated.

    Time frame: 28 days

07

Results

Posted Jul 16, 2021

Participant flow

Participant flow — Overall Study
Milestone10 mg BCV BIW RT10 mg BCV BIW HCT20 mg BCV QW HCTPlacebo BIW HCT40 mg BCV QW RT40 mg BCV QW HCTPlacebo QW RTPlacebo QW HCT
Started11128844
Completed10128743
Not completed01000101
Withdrew: Patient request01000000
Withdrew: Protocol violation00000001
Withdrew: Subject not dosed00000100

Outcome measures

PrimaryNumber of Adverse Events in Post-Transplant Patients With BK Virus Viruria

The primary objective of this study was to determine the safety and tolerability of brincidofovir (BCV) in post-transplant patients with BK virus viruria. Safety measures included adverse events, clinical laboratory values, vital signs, and renal and gastrointestinal function.

Time frame:
35 days (Day 0 to Day 35)
Reported as:
Count of participants · Participants
Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria
Participants10 mg BCV BIW RT10 mg BCV BIW HCT20 mg BCV BIW HCTPlacebo BIW HCT40 mg BCV QW RT40 mg BCV QW HCTPlacebo QW RTPlacebo QW HCT
Subjects who experienced at least 1 an adverse event11128734
Subjects who did not experience an adverse event00000010
SecondaryPercentage of Patients Who Achieved BK Viruria Resolution

The percentage of subjects who cleared the virus was calculated. Concentrations below the lower limit of quantification were indicated as below the limit of quantitation and were considered "cleared".

Time frame:
28 days
Reported as:
Count of participants · Participants
Percentage of Patients Who Achieved BK Viruria Resolution
Participants40 mg BCV QWPlacebo
HCT recipients — Subjects who cleared viruria10
HCT recipients — Subjects who did not clear viruria64
RT Recipients — Subjects who cleared viruria10
RT Recipients — Subjects who did not clear viruria74
SecondaryNumber of Patients Who Achieved a Clinically Significant Decrease in BK Viruria

A 2-log drop in viruria or viremia or clearance of virus was considered significant. Percentages of subjects with a 2-log drop in viral load were calculated.

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Patients Who Achieved a Clinically Significant Decrease in BK Viruria
Participants40 mg BCV QWPlacebo QW
HCT recipients — Subjects with 2-log drop from Day 011
HCT recipients — Subjects without 2-log drop from Day 063
RT Recipients — Subjects with 2-log drop from Day 000
RT Recipients — Subjects without 2-log drop from Day 084

Adverse events

Collected over Day 0 to Day 35. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg BCV BIW RT—1/1 (100%)1/1 (100%)
10 mg BCV BIW HCT—0/1 (0%)1/1 (100%)
20 mg BCV QW HCT—0/1 (0%)1/1 (100%)
Placebo BIW HCT—0/2 (0%)2/2 (100%)
40 mg BCV QW RT—0/8 (0%)8/8 (100%)
40 mg BCV QW HCT—2/7 (28.6%)7/7 (100%)
Placebo QW RT—0/4 (0%)3/4 (75%)
Placebo QW HCT—1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
Event10 mg BCV BIW RT10 mg BCV BIW HCT20 mg BCV QW HCTPlacebo BIW HCT40 mg BCV QW RT40 mg BCV QW HCTPlacebo QW RTPlacebo QW HCT
Pancreas transplant rejectionImmune system disorders1/10/10/10/20/80/70/40/4
Acute graft versus host disease in intestineImmune system disorders0/10/10/10/20/80/70/41/4
PyrexiaGeneral disorders0/10/10/10/20/80/70/41/4
MethemoglobinemiaBlood and lymphatic system disorders0/10/10/10/20/80/70/41/4
HaematuriaRenal and urinary disorders0/10/10/10/20/81/70/40/4
OliguriaRenal and urinary disorders0/10/10/10/20/81/70/40/4
Acute graft versus host disease skinImmune system disorders0/10/10/10/20/81/70/40/4
PneumoniaInfections and infestations0/10/10/10/20/81/70/40/4
Most frequent other events
Showing 10 of 86
Most frequent other events
Event10 mg BCV BIW RT10 mg BCV BIW HCT20 mg BCV QW HCTPlacebo BIW HCT40 mg BCV QW RT40 mg BCV QW HCTPlacebo QW RTPlacebo QW HCT
DiarrhoeaGastrointestinal disorders0/11/10/10/23/82/70/42/4
Blood amylase increasedInvestigations1/10/10/10/21/80/70/40/4
Lipase increasedInvestigations1/10/10/10/21/80/70/40/4
OsteopeniaMusculoskeletal and connective tissue disorders0/10/10/12/20/80/70/42/4
EcchymosisSkin and subcutaneous tissue disorders0/10/11/10/20/80/70/40/4
CellulitisInfections and infestations0/10/11/10/20/80/70/40/4
Oedema peripheralGeneral disorders0/10/10/10/20/84/70/40/4
NauseaGastrointestinal disorders0/10/10/11/21/83/70/42/4
VomitingGastrointestinal disorders0/10/10/10/20/81/70/42/4
FatigueGeneral disorders0/10/10/11/21/82/70/41/4

Baseline characteristics

1 HCT subject in the 40 mg BCV QW treatment arm was not dosed with BCV and, therefore, is not included in this analysis.

Age, Continuous
Age, Continuous(years)10 mg BCV BIW20 mg BCV QWPlacebo BIW40 mg BCV QWPlacebo QWTotal
Mean40 ± 1060 ± 060 ± 255.5 ± 15.1451.0 ± 10.4651.5 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)10 mg BCV BIW20 mg BCV QWPlacebo BIW40 mg BCV QWPlacebo QWTotal
Female001348
Male21112420
Type of transplant received
Type of transplant received(Participants)10 mg BCV BIW20 mg BCV QWPlacebo BIW40 mg BCV QWPlacebo QWTotal
Hematopoietic stem cell transplant recipients1127415
Renal transplant recipients1008413
08

Study locations

15 sites
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • University of California, San Francisco
    San Francisco, California 94143-0780, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Tulane Center for Abdominal Transplant
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Medical Institutions
    Baltimore, Maryland 21287, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Mt. Sinai Medical Center
    New York, New York 10029, United States
  • UNC Kidney Center
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15260, United States
  • University of Vermont
    Burlington, Vermont 05405, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 19024, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2009 to primary completion in Oct 2010, 11 months.

Results were first posted in Jul 2021, 10 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2008
First posted
Nov 19, 2008
StartActual
Nov 2009
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Jul 16, 2021
Last update
Aug 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00793598
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
Nov 19, 2008
Start date
Nov 2009
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Jul 16, 2021
Last update
Aug 16, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion